Thoracic Oncology
-
Panelists to preview updated CHEST guidelines on pneumothorax, persistent air leak
Kamran Mahmood, MD, MPH, FCCP, will chair a Tuesday session that will offer a sneak peek at the clinical issues in CHEST guidelines scheduled to be released next year.
-
Revolutionizing respiratory care: Bedside ultrasound for diaphragm assessment
Diaphragm ultrasound is a safe, noninvasive tool that evaluates respiratory muscle function, aiding in diagnosis, weaning from ventilation, and management of lung disease.
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
New data confirms ILD as lung cancer risk factor
Bradford C. Bemiss, MD, and Claudia Henschke, PhD, MD, said the study clearly shows patients with interstitial lung disease have an increased risk of lung cancer.
-
Varenicline found effective for nicotine vaping cessation in youth
Researcher A. Eden Evins, MD, said she was surprised by the ineffectiveness of behavioral therapy alone.
-
EBUS nodal staging in early-stage non-small cell lung cancer
EBUS-TBNA disrupted the field of bronchoscopy by offering a minimally invasive, real-time imaging approach to biopsy, but recent data have emerged that show routine use of EBUS may warrant scrutiny.
-
Get informed and involved with smoking cessation strategies, advocacy
Sessions will equip attendees with the latest information about the health consequences of e-cigarettes and cannabis. Because the landscape has evolved so much recently, misconceptions are common—even among clinicians, said Evan Stepp, MD, FCCP.
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
In our navigational bronchoscopy ERA
The VERITAS trial is a turning point for interventional pulmonology, ushering in an era of high-quality comparative effectiveness trials poised to transform our approach to technology evaluation, implementation, and, ultimately, patient care.
-
Opening the flood gates: Pleural complications of immune checkpoint inhibitors
The pulmonary and medical oncology community must start to consider pleural complications as a potential risk of immune checkpoint inhibitor therapy.
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
POCUS for temporary intracorporeal and extracorporeal mechanical circulatory support
POCUS use refines diagnostic accuracy, enhances procedural safety, and optimizes outcomes for patients requiring advanced circulatory support.
